• Jordan R Covvey.
• Division of Clinical, Social and Administrative Sciences, Duquesne University Mylan School of Pharmacy, 600 Forbes Ave., Pittsburgh, PA 15282, USA. Electronic address: covveyj@duq.edu.
• Res Social Adm Pharm. 2015 Nov 1; 11 (6): 901-8.

AbstractOpioids have become a mainstay of treatment for pain in the United States, with over 250 million prescription issued in 2012 alone. The increased prescribing of these medications has also contributed to the unintended consequence of a widening prevalence of abuse and misuse, and therefore safety has become a top agenda item for both government and health care providers alike. The move toward new abuse-deterrent formulation technologies, enhanced regulatory requirements from the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA), and developments in national/state policies have worked together to target a goal of promoting safer clinician prescribing, pharmacy dispensing and patient use of opioids. Hydrocodone in particular, as the most widely prescribed opioid product, has recently been subject to a myriad of changes, both through the federal rescheduling of hydrocodone-combination products (HCPs) to Schedule II, as well as the introduction of two new extended-release formulations to the USA market. These efforts represent a first step toward tackling the opioid harms epidemic, although continuing follow-up through research and policy implementation is needed to see any measureable impact on safety in the future.Copyright © 2015 Elsevier Inc. All rights reserved.

30 keywords...

hide…